Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746989 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
A clinical trial of Gout, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 294,878
- Enrollment target
- 1
- Study location
NCT04746989 is a study of Gout that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 294,878 participants, above the 215-participant average among 34 other Gout trials with a reported enrollment target (137053% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04746989, a study of Gout, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 294,878 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Probenecid
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294,878 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746989
The ClinicalTrials.gov registry entry for NCT04746989 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 294,878 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 215-participant average among 34 other Gout trials with a reported enrollment target (137053% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.
NCT04746989 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04746989 about?
NCT04746989 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT04746989?
This trial is currently completed. The enrollment target is 294,878 participants. The study started on 2021-02-01. Estimated completion is 2023-12-31.
What conditions does trial NCT04746989 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT04746989?
The interventions under investigation include: Allopurinol (DRUG), Probenecid (DRUG).
Who is sponsoring clinical trial NCT04746989?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746989 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
RECRUITING · Phase 4
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.